Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

41.77 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 41.08 (1)
Ask (Size) 42.77 (1)
Prev. Close 41.77
Today's Range 41.77 - 41.77
52wk Range 34.74 - 51.18
Shares Outstanding 227,985,334
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock
Qiagen NV (NYSE: QGEN) has a steady income from selling tools for preparing samples and diagnostics. 
Via Benzinga
Where Qiagen Stands With Analysts
Via Benzinga

Performance

YTD
-16.34%
-16.34%
1 Month
+9.78%
+9.78%
3 Month
-1.60%
-1.60%
6 Month
-10.33%
-10.33%
1 Year
-16.19%
-16.19%

More News

Read More
These Companies Helped The German DAX Index Hit Its All-time High
Via Talk Markets
Analyst Expectations for Qiagen's Future
Via Benzinga
Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends
Via Benzinga
Preview: Qiagen's Earnings
Via Benzinga
Analyst Expectations for Qiagen's Future
Via Benzinga
Will Chart Analysts Notice Bad Omen on Qiagen's Chart
Via Benzinga
Earnings Scheduled For October 30, 2023
Via Benzinga
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
Via Benzinga
Exposures COVID-19
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
From Bio-Rad Laboratories, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
The 3 Most Promising Biotech Stocks to Buy Now
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
From QIAGEN N.V.
Via Business Wire
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
From QIAGEN N.V.
Via Business Wire
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
From QIAGEN N.V.
Via Business Wire
Genetic Technologies Shares Jump After Strategic Alliance With Qiagen
Via Benzinga
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
Via Benzinga
QIAGEN Acquires Verogen Strengthening Its Position In Human ID / Forensics
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.